Division Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale (INSERM), U1251, Marseille Medical Genetics (MMG), Marseille, France.
Endocr Relat Cancer. 2018 Nov 1;25(11):R519-R544. doi: 10.1530/ERC-18-0025.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a group of heterogeneous tumors whose incidence increased over the past few years. Around half of patients already present with metastatic disease at the initial diagnosis. Despite extensive efforts, cytotoxic and targeted therapies have provided only limited efficacy for patients with metastatic GEP-NETs, mainly due to the development of a certain state of resistance. One factor contributing to both the failure of systemic therapies and the emergence of an aggressive tumor phenotype may be the tumor microenvironment (TME), comprising dynamic and adaptative assortment of extracellular matrix components and non-neoplastic cells, which surround the tumor niche. Accumulating evidence shows that the TME can simultaneously support both tumor growth and metastasis and contribute to a certain state of resistance to treatment. In this review, we summarize the current knowledge of the TME of GEP-NETs and discuss the current therapeutic agents that target GEP-NETs and those that could be of interest in the (near) future.
胃肠胰神经内分泌肿瘤(GEP-NETs)是一组异质性肿瘤,其发病率在过去几年中有所增加。约有一半的患者在初始诊断时已经存在转移性疾病。尽管进行了广泛的努力,但细胞毒性和靶向治疗对转移性 GEP-NET 患者的疗效有限,主要是由于出现了一定程度的耐药性。导致全身治疗失败和侵袭性肿瘤表型出现的一个因素可能是肿瘤微环境(TME),它由围绕肿瘤龛的细胞外基质成分和非肿瘤细胞的动态和适应性混合物组成。越来越多的证据表明,TME 既能支持肿瘤生长和转移,又能导致对治疗的一定程度的耐药性。在这篇综述中,我们总结了 GEP-NETs 的 TME 的现有知识,并讨论了目前针对 GEP-NETs 的治疗药物以及未来可能有兴趣的药物。